Epigenetics in non-small cell lung cancer: From basics to therapeutics

Translational Lung Cancer Research

Volumn 5, Issue 2, 2016, Pages 155-171

  Ansari, Junaid ^a   Shackelford, Rodney E ^b   El Osta1, Hazem ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; DNA methylation; Epigenetic therapy; Histone deacetylases (HDACs); Lung cancer; MicroRNA

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CARBOPLATIN; CAROTENE; CC 486; CI 944; CYTOSINE; DACINOSTAT; DNA; ENTINOSTAT; FLUCYTOSINE DEOXYRIBOSIDE; FLUOROURACIL; GEFITINIB; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MOCETINOSTAT; OSU HDAC 44; PACLITAXEL; PEMBROLIZUMAB; ROMIDEPSIN; RRX 001; SALINOSPORAMIDE A; SL 142; SL 325; SULINDAC; TETRAHYDROURIDINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

AEROSOL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CYTOTOXICITY; DNA METHYLATION; ENZYME INHIBITION; EPIGENETICS; GENE SILENCING; GENE THERAPY; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; MOLECULAR PATHOLOGY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING;

EID: 84965067264     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.21037/tlcr.2016.02.02     Document Type: Article

References (169)

1. SEER. SEER Stat Fact Sheets: Lung and Bronchus Cancer 2015. Available online: http://seer.cancer.gov/statfacts/ html/lungb.html
2. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol 2015;16:e342-51.
3. Shackelford RE, Vora M, Mayhall K, et al. ALKrearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer 2014;5:1-14.
4. Waddington CH. Preliminary Notes on the Development of the Wings in Normal and Mutant Strains of Drosophila. Proc Natl Acad Sci U S A 1939;25:299-307.
5. Holliday R. The inheritance of epigenetic defects. Science 1987;238:163-70.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
8. Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. Biomark Med 2013;7:49-58.
9. Brzezianska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis. Mol Biol Rep 2013;40:309-25.
10. Mehta A, Dobersch S, Romero-Olmedo AJ, et al. Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev 2015;34:229-41.
11. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010-22.
12. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 2008;105:252-7.
13. Kim M, Trinh BN, Long TI, et al. Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Res 2004;32:5742-9.
14. Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009;124:81-7.
15. Zöchbauer-Müller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in nonsmall cell lung cancers. Cancer Res 2001;61:249-55.
16. Sargurupremraj M, Wjst M. Transposable elements and their potential role in complex lung disorder. Respir Res 2013;14:99.
17. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012;22:1197-211.
18. Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113:264-8.
19. Halkidou K, Gaughan L, Cook S, et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89.
20. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25:261-309.
21. Damiani LA, Yingling CM, Leng S, et al. Carcinogeninduced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 2008;68:9005-14.
22. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28.
23. Sterlacci W, Tzankov A, Veits L, et al. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol 2011;6:1649-57.
24. Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 2010;29:1681-90.
25. Forde PM, Brahmer JR, Kelly RJ. New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer. Clin Cancer Res 2014;20:2244-8.
26. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
27. Patel K, Dickson J, Din S, et al. Targeting of 5-aza-2'- deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010;38:4313-24.
28. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10.
29. Zhou Q, Agoston AT, Atadja P, et al. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 2008;6:873-83.
30. Lin RK, Wu CY, Chang JW, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010;70:5807-17.
31. Kim H, Kwon YM, Kim JS, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006;107:1042-9.
32. Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007;55:205-13.
33. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
34. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012;21:430-46.
35. Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
36. Liu SV, Fabbri M, Gitlitz BJ, et al. Epigenetic therapy in lung cancer. Front Oncol 2013;3:135.
37. Momparler RL, Ayoub J. Potential of 5-aza-2'- deoxycytidine #Decitabine# a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001;34 Suppl 4:S111-5.
38. Momparler RL, Bouffard DY, Momparler LF, et al. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358-68.
39. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12:5777-85.
40. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-60.
41. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
42. Liu Y, Lan Q, Siegfried JM, et al. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006;8:46-51.
43. Lin RK, Hsieh YS, Lin P, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010;120:521-32.
44. O'Hagan HM, Wang W, Sen S, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011;20:606-19.
45. Belinsky SA. Unmasking the lung cancer epigenome. Annu Rev Physiol 2015;77:453-74.
46. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 2008;14:7237-45.
47. Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab?-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Nonsmall Cell Lung Cancer (abound2L). ClinicalTrials. gov 2014:NCT 02250326. Available online: https:// clinicaltrials.gov/ct2/show/NCT02250326?term=NCT02 250326&rank=1
48. RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (TRIPLE THREAT). ClinicalTrials.gov 2015:NCT 02489903. Available online: https://clinicaltrials.gov/ct2/show/NCT02489903?term= NCT02489903&rank=1
49. Inhaled Azacitidine in Patients With Advanced Non-small Cell Lung Cancer. ClinicalTrials.gov 2014:NCT02009436. Available online: https://clinicaltrials.gov/ct2/show/record/ NCT02009436?term=NCT02009436&rank=1
50. Luger K, Mäder AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-60.
51. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
52. Riggs MG, Whittaker RG, Neumann JR, et al. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977;268:462-4.
53. Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975;5:319-22.
54. Miyanaga A, Gemma A, Noro R, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008;7:1923-30.
55. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-28.
56. Ozdag H, Teschendorff AE, Ahmed AA, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006;7:90.
57. Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004;46:171-8.
58. Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011;74:300-4.
59. Minamiya Y, Ono T, Saito H, et al. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol 2010;31:533-9.
60. Bartling B, Hofmann HS, Boettger T, et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 2005;49:145-54.
61. Imre G, Gekeler V, Leja A, et al. Histone deacetylase inhibitors suppress the inducibility of nuclear factorkappaB by tumor necrosis factor-alpha receptor-1 downregulation. Cancer Res 2006;66:5409-18.
62. Kim HR, Kim EJ, Yang SH, et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp Mol Med 2006;38:616-24.
63. Zhang F, Zhang T, Teng ZH, et al. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in nonsmall cell lung cancer (NSCLC) cells. Cancer Biol Ther 2009;8:823-31.
64. Seo SK, Jin HO, Woo SH, et al. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 2011;6:1313-9.
65. Li CT, Hsiao YM, Wu TC, et al. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. J Cell Biochem 2011;112:3044-53.
66. Komatsu N, Kawamata N, Takeuchi S, et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006;15:187-91.
67. Stojanovic D, Nikic D, Lazarevic K. The level of nickel in smoker's blood and urine. Cent Eur J Public Health 2004;12:187-9.
68. Zhou X, Li Q, Arita A, et al. Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol Appl Pharmacol 2009;236:78-84.
69. Cantone L, Nordio F, Hou L, et al. Inhalable metal-rich air particles and histone H3K4 dimethylation and H3K9 acetylation in a cross-sectional study of steel workers. Environ Health Perspect 2011;119:964-9.
70. Han S, Fukazawa T, Yamatsuji T, et al. Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids. PLoS One 2010;5:e13834.
71. Shieh JM, Wei TT, Tang YA, et al. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. PLoS One 2012;7:e30240.
72. Hwang JJ, Kim YS, Kim MJ, et al. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. Anticancer Drugs 2009;20:815-21.
73. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008;7:759-68.
74. Gray J, Cubitt CL, Zhang S, et al. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 2012;13:614-22.
75. Tang YA, Wen WL, Chang JW, et al. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One 2010;5:e12417.
76. Zhang Q, Feng W, Zhou H, et al. Advances in preclinical small molecules for the treatment of NSCLC. Expert Opin Ther Pat 2009;19:731-51.
77. Niesen MI, Blanck G. Rescue of major histocompatibility- DR surface expression in retinoblastoma-defective, nonsmall cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 2009;32:480-2.
78. Belinsky SA, Grimes MJ, Picchi MA, et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011;71:454-62.
79. Cuneo KC, Fu A, Osusky K, et al. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 2007;18:793-800.
80. Beckers T, Burkhardt C, Wieland H, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007;121:1138-48.
81. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31.
82. Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008;22:3172-83.
83. Heller G, Weinzierl M, Noll C, et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR- 193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 2012;18:1619-29.
84. Watanabe K, Emoto N, Hamano E, et al. Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 2012;130:2580-90.
85. Xi S, Xu H, Shan J, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest 2013;123:1241-61.
86. Esteller M. Cancer Epigenetics for the 21st Century: What's Next? Genes Cancer 2011;2:604-6.
87. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
88. Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
89. Boivin AJ, Momparler LF, Hurtubise A, et al. Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 2002;13:869-74.
90. Zhu WG, Lakshmanan RR, Beal MD, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-33.
91. Chu BF, Karpenko MJ, Liu Z, et al. Phase I study of 5-aza- 2'-deoxycytidine in combination with valproic acid in nonsmall- cell lung cancer. Cancer Chemother Pharmacol 2013;71:115-21.
92. Lin J, Gilbert J, Rudek MA, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 2009;15:6241-9.
93. Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-38.
94. Stathis A, Hotte SJ, Chen EX, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 2011;17:1582-90.
95. Wrangle J, Wang W, Koch A, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 2013;4:2067-79.
96. Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery. ClinicalTrials.gov 2010:NCT01207726. Available online: https://clinicaltrials.gov/ct2/show/NCT0 1207726?term=NCT01207726&rank=1
97. Shiau RJ, Chen KY, Wen YD, et al. Genistein and beta-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells. Eur J Nutr 2010;49:19-25.
98. Millward M, Price T, Townsend A, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2012;30:2303-17.
99. Chien CW, Yao JH, Chang SY, et al. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicol Appl Pharmacol 2011;257:59-66.
100. Seo SK, Jin HO, Lee HC, et al. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 2008;73:1005-12.
101. Reed MD, Tellez CS, Grimes MJ, et al. Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 2013;109:1775-81.
102. Li J, Li WX, Bai C, et al. Particulate matter-induced epigenetic changes and lung cancer. Clin Respir J 2015. [Epub ahead of print].
103. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011;108:3713-8.
104. Liloglou T, Bediaga NG, Brown BR, et al. Epigenetic biomarkers in lung cancer. Cancer Lett 2014;342:200-12.
105. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3:e486.
106. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23- 25. Am J Hum Genet 2004;75:460-74.
107. Smith LT, Lin M, Brena RM, et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A 2006;103:982-7.
108. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 1999;59:2307-12.
109. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007;3:1709-23.
110. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
111. Toyota M, Ho C, Ohe-Toyota M, et al. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5' CpG island in human tumors. Cancer Res 1999;59:4535-41.
112. Estécio MR, Yan PS, Ibrahim AE, et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007;17:1529-36.
113. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003;63:4620-5.
114. Hoque MO, Kim MS, Ostrow KL, et al. Genomewide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008;68:2661-70.
115. Mungall AJ, Palmer SA, Sims SK, et al. The DNA sequence and analysis of human chromosome 6. Nature 2003;425:805-11.
116. Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-85.
117. Ito M, Ito G, Kondo M, et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 2005;225:131-9.
118. Wang M, Vikis HG, Wang Y, et al. Identification of a novel tumor suppressor gene p34 on human chromosome 6q25. 1. Cancer Res 2007;67:93-9.
119. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
120. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
121. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999;107 Suppl 1:5-24.
122. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-6.
123. Brabender J, Usadel H, Metzger R, et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 2003;9:223-7.
124. Gomes A, Reis-Silva M, Alarcão A, et al. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol 2014;20:20-30.
125. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-6.
126. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 2001;20:1765-70.
127. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003;10:356-64.
128. Shivapurkar N, Toyooka S, Eby MT, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002;1:65-9.
129. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-84.
130. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007;58:131-8.
131. Kim DS, Kim MJ, Lee JY, et al. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer 2007;110:2785-92.
132. Heller G, Fong KM, Girard L, et al. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 2006;25:959-68.
133. Grote HJ, Schmiemann V, Kiel S, et al. Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 2004;110:751-5.
134. Virmani AK, Rathi A, Zöchbauer-Müller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7.
135. Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010;10:600.
136. Sato K, Tomizawa Y, Iijima H, et al. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 2006;15:129-35.
137. Korch C, Hagblom P. In-vivo-modified gonococcal plasmid pJD 1. A model system for analysis of restriction enzyme sensitivity to DNA modifications. Eur J Biochem 1986;161:519-24.
138. Waalwijk C, Flavell RA. MspI, an isoschizomer of hpaII which cleaves both unmethylated and methylated hpaII sites. Nucleic Acids Res 1978;5:3231-6.
139. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74:481-514.
140. Tost J, Gut IG. Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. Methods Mol Biol 2007;373:89-102.
141. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005;102:15785-90.
142. Ehrich M, Field JK, Liloglou T, et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006;66:10911-8.
143. Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994;6:236-44.
144. Zhang X, Jacobsen SE. Genetic analyses of DNA methyltransferases in Arabidopsis thaliana. Cold Spring Harb Symp Quant Biol 2006;71:439-47.
145. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 2005;85:1172-80.
146. Jung M, Kadam S, Xiong W, et al. MIRA-seq for DNA methylation analysis of CpG islands. Epigenomics 2015;7:695-706.
147. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011;303:21-8.
148. Salazar F, Molina MA, Sanchez-Ronco M, et al. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 2011;72:84-91.
149. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
150. Bianchi F, Nicassio F, Veronesi G, et al. Circulating microRNAs: next-generation biomarkers for early lung cancer detection. Ecancermedicalscience 2012;6:246.
151. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503.
152. Gallardo E, Navarro A, Viñolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected nonsmall- cell lung cancer. Carcinogenesis 2009;30:1903-9.
153. Tang R, Liang L, Luo D, et al. Downregulation of MiR- 30a is Associated with Poor Prognosis in Lung Cancer. Med Sci Monit 2015;21:2514-20.
154. Guo W, Zhang Y, Zhang Y, et al. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med 2015;36:1720-6.
155. Bai Y, Wang YL, Yao WJ, et al. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol 2015;8:824-9.
156. Ge H, Li B, Hu WX, et al. MicroRNA-148b is downregulated in non-small cell lung cancer and associated with poor survival. Int J Clin Exp Pathol 2015;8:800-5.
157. Shen H, Shen J, Wang L, et al. Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother 2015;69:301-5.
158. Zhu D, Chen H, Yang X, et al. Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients. Diagn Pathol 2014;9:198.
159. Shao Y, Geng Y, Gu W, et al. Prognostic significance of microRNA-375 downregulation in solid tumors: a metaanalysis. Dis Markers 2014;2014:626185.
160. Zhong KZ, Chen WW, Hu XY, et al. Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer. Int J Clin Exp Pathol 2014;7:4545-51.
161. Han L, Zhang G, Zhang N, et al. Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol 2014;31:129.
162. Kim MK, Jung SB, Kim JS, et al. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch 2014;465:463-71.
163. Zhao W, Zhao JJ, Zhang L, et al. Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Med 2015;8:14759-63.
164. Mavridis K, Gueugnon F, Petit-Courty A, et al. The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. Br J Cancer 2015;112:1527-35.
165. Yin QW, Sun XF, Yang GT, et al. Increased expression of microRNA-150 is associated with poor prognosis in nonsmall cell lung cancer. Int J Clin Exp Pathol 2015;8:842-6.
166. Tejero R, Navarro A, Campayo M, et al. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One 2014;9:e101899.
167. Zhao Q, Cao J, Wu YC, et al. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. Am J Cancer Res 2015;5:1692-705.
168. Yang L, Yang J, Li J, et al. MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. Sci Rep 2015;5:13677.
169. Zhang Y, Li H, Han J, et al. Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer. Int J Clin Exp Pathol 2015;8:1967-72.